{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:38:44Z","timestamp":1790008724728,"version":"4.0.1"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n There is a global call to end cervical cancer, and various jurisdictions are still determining optimal strategies to accelerate elimination. Human papillomavirus (HPV)-negative testing confers lower risk of future precancer vs normal cytology; high-quality longitudinal data are needed comparing risk after a negative HPV test vs negative cotest (HPV and cytology).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare long-term risk of cervical precancer based on HPV, cytology, and cotest screening results.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study linked data from a randomized clinical trial to a comprehensive screening program in British Columbia. Participants were recruited between 2006 and 2012 and followed from trial exit to 10 years postexit. Eligible participants were women who completed trial exit cotesting. Data were analyzed between January and April 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n HPV and cytology status from exit cotesting were considered, stratified by status of each test.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Cumulative risk of precancer was calculated over follow-up using Kaplan-Meier techniques. Risk was compared among groups who tested HPV-negative with normal cytology, HPV-negative with abnormal cytology, HPV-positive with normal cytology, and HPV-positive with abnormal cytology. Additionally, risk among those who were HPV-negative (regardless of cytology result), with normal cytology (regardless of HPV results), or were cotest negative were compared in order to simulate outcomes in primary HPV screening, cytology, and cotest programs, respectively.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In this cohort of 8078 women (median [IQR] age at exit screen, 49 [41-57] years; 1636 Asian [22.4%], 223 Indigenous [3.0%], 5568 White [76.1%]) who participated in a British Columbia\u2013based cervical cancer screening trial, the HPV-positive with abnormal cytology group had the highest cumulative incidence risk (CIR) of cervical intraepithelial neoplasia grade 2 or higher at the end of follow-up (CIR, 43.47%; 95% CI, 23.45%-58.26%), followed by the HPV-positive and cytology-negative group (CIR, 22.21%; 95% CI, 11.49%-31.62%). The HPV-negative with abnormal cytology (CIR, 4.83%; 95% CI, 0%-10.03%) and the HPV-negative with normal cytology (CIR, 0.37%; 95% CI, 0.13%-0.60%) groups had significantly lower CIR at the end of follow-up. Less than 1% of the population was HPV-negative with abnormal cytology (69 of 8078 [0.85%]). Women who were HPV-negative regardless of cytology results (CIR, 0.41%; 95% CI, 0.17%-0.65%) had a similar risk as those who cotested negative (CIR, 0.37%; 95% CI, 0.13%-0.60%); both groups had lower risk than those with normal cytology results (regardless of HPV result) (CIR, 1.28%; 95% CI, 0.78%-1.78%) throughout follow-up.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of cervical cancer screen testing approaches and risk of cervical precancer, after a negative HPV test (regardless of cytology results) risk of precancer remained acceptably low throughout long-term follow-up. This suggests that cotesting yielded limited benefits, while increasing costs, relative to primary HPV testing.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.1304","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:00:30Z","timestamp":1773241230000},"page":"e261304","source":"Crossref","is-referenced-by-count":4,"title":["HPV, Cytology, and Cotest Cervical Cancer Screening and the Risk of Precancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Anna","family":"Gottschlich","sequence":"first","affiliation":[{"name":"Women\u2019s Health Research Institute, BC Women\u2019s Hospital and Health Services, Vancouver, British Columbia, Canada"},{"name":"Department of Oncology, Wayne State University, Detroit, Michigan"},{"name":"Population Sciences and Disparities Research Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie W.","family":"Smith","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Institute, BC Women\u2019s Hospital and Health Services, Vancouver, British Columbia, Canada"},{"name":"Population Health Sciences, BC Cancer, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Hong","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Institute, BC Women\u2019s Hospital and Health Services, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smritee","family":"Dabee","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Institute, BC Women\u2019s Hospital and Health Services, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovedeep","family":"Gondara","sequence":"additional","affiliation":[{"name":"British Columbia Cervix Screening Program, BC Cancer, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrel","family":"Cook","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Elwood","family":"Martin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Melnikow","sequence":"additional","affiliation":[{"name":"Center for Healthcare Policy and Research, University of California, Davis, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Peacock","sequence":"additional","affiliation":[{"name":"Population Health Sciences, BC Cancer, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Proctor","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Institute, BC Women\u2019s Hospital and Health Services, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Population Health Sciences, BC Cancer, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Stuart","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mel","family":"Krajden","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina S.","family":"Ogilvie","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Institute, BC Women\u2019s Hospital and Health Services, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"2","key":"zoi260070r1","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob Health"},{"key":"zoi260070r2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bpobgyn.2017.08.010","article-title":"Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage.","volume":"47","author":"Brotherton","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"zoi260070r3","doi-asserted-by":"publisher","first-page":"b2968","DOI":"10.1136\/bmj.b2968","article-title":"Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data.","volume":"339","author":"Sasieni","year":"2009","journal-title":"BMJ"},{"issue":"7","key":"zoi260070r5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer us preventive services task force recommendation statement.","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"zoi260070r7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2018.7464","article-title":"Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial.","volume":"320","author":"Ogilvie","year":"2018","journal-title":"JAMA"},{"issue":"9916","key":"zoi260070r8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"zoi260070r11","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/ijc.32950","article-title":"A study of the risks of CIN3+ detection after multiple rounds of HPV testing: results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.","volume":"147","author":"Hammer","year":"2020","journal-title":"Int J Cancer"},{"issue":"6","key":"zoi260070r13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/ijc.34039","article-title":"Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial.","volume":"151","author":"Gottschlich","year":"2022","journal-title":"Int J Cancer"},{"issue":"11","key":"zoi260070r14","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1002\/ijc.30385","article-title":"Human papillomavirus testing versus cytology in primary cervical cancer screening: end-of-study and extended follow-up results from the Canadian cervical cancer screening trial.","volume":"139","author":"Isidean","year":"2016","journal-title":"Int J Cancer"},{"key":"zoi260070r15","doi-asserted-by":"publisher","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"issue":"11","key":"zoi260070r16","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1007\/s11606-016-3772-5","article-title":"Cost-effectiveness of primary HPV testing, cytology and co-testing as cervical cancer screening for women above age 30 years.","volume":"31","author":"Jin","year":"2016","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi260070r17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2018.7464","article-title":"Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial.","volume":"320","author":"Ogilvie","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"zoi260070r19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"issue":"6","key":"zoi260070r20","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.3390\/curroncol30060431","article-title":"2023 Canadian Colposcopy Guideline: a risk-based approach to management and surveillance of cervical dysplasia.","volume":"30","author":"Willows","year":"2023","journal-title":"Curr Oncol"},{"issue":"51","key":"zoi260070r21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta13510","article-title":"ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.","volume":"13","author":"Kitchener","year":"2009","journal-title":"Health Technol Assess"},{"issue":"16","key":"zoi260070r22","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa073204","article-title":"Human papillomavirus and Papanicolaou tests to screen for cervical cancer.","volume":"357","author":"Naucler","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260070r23","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/j.ygyno.2007.07.021","article-title":"The New Technologies for Cervical Cancer Screening randomised controlled trial: an overview of results during the first phase of recruitment.","volume":"107","author":"Ronco","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"zoi260070r24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(11)70296-0","article-title":"Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.","volume":"13","author":"Rijkaart","year":"2012","journal-title":"Lancet Oncol"},{"issue":"16","key":"zoi260070r25","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa071430","article-title":"Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.","volume":"357","author":"Mayrand","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260070r26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016700","article-title":"Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.","volume":"8","author":"Canfell","year":"2018","journal-title":"BMJ Open"},{"key":"zoi260070r27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ygyno.2023.11.036","article-title":"Similar effectiveness with primary HPV and cytology screening\u2014long-term follow-up of randomized cervical cancer screening trial.","volume":"180","author":"Vahteristo","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"9916","key":"zoi260070r28","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"zoi260070r29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jasc.2024.12.003","article-title":"American Society of Cytopathology\u2019s cytopathology workforce survey in the United States.","volume":"14","author":"Satturwar","year":"2025","journal-title":"J Am Soc Cytopathol"},{"key":"zoi260070r4","unstructured":"World Health Organization. Draft: Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem. Published online April 5, 2020. Accessed July 21, 2025. https:\/\/cdn.who.int\/media\/docs\/default-source\/cervical-cancer\/cervical-cancer-elimination-strategy-20200508b99e1a91e6ac490a9ec29e3706bdfacf_c2ff5d7a-7013-4df1-a690-2a35d88434c5.pdf?sfvrsn=b8690d1a_22"},{"key":"zoi260070r6","unstructured":"World Health Organization. Guideline For Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention, Second Edition. Published online 2021. Accessed July 21, 2025. https:\/\/iris.who.int\/items\/16652e25-1204-4d55-910b-9df5fd952f80"},{"key":"zoi260070r9","unstructured":"Australian Institute of Health and Welfare. National Cervical Cancer Screening Program monitoring report 2020. December 1, 2020. Accessed July 21, 2025. https:\/\/www.aihw.gov.au\/reports\/cancer-screening\/national-cervical-screening-monitoring-report-2020\/summary"},{"key":"zoi260070r10","unstructured":"Netherlands Comprehensive Cancer Organization. National Monitoring of the Cervical Cancer Screening Programme in the Netherlands 2019. Published online October 2020. Accessed July 21, 2025. https:\/\/iknl.nl\/getmedia\/dada853c-4945-4ffa-81c2-f5e634ed06a5\/2019_Monitor-cervical-cancer-screening_The-Netherlands.pdf"},{"key":"zoi260070r12","unstructured":"US Preventive Services Task Force. Draft recommendation statement cervical cancer: screening. Published online December 10, 2024. Accessed July 21, 2025. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/draft-recommendation\/cervical-cancer-screening-adults-adolescents#fullrecommendationstart (2024)."},{"key":"zoi260070r18","unstructured":"BC Cancer Agency. BC Cancer cervix screening 2018 program results. Provincial Health Services Authority report. May 2018. Accessed July 21, 2025. https:\/\/www.bccancer.bc.ca\/screening\/Documents\/Cervix_ProgramResults2016_OPT.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846208\/gottschlich_2026_oi_260070_1772645493.53136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:00:33Z","timestamp":1773241233000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.1304","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}